Specialty pharmacist integration into an outpatient neurology clinic improves pimavanserin access

INTRODUCTION: Access to pimavanserin, the only Parkinson disease–related psychosis treatment approved by the FDA, is restricted by insurance requirements, a limited distribution network, and high costs. Following initiation, patients require monitoring for safety and effectiveness. The primary objec...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Ment Health Clin
Autors principals: Livezey, Sabrina, Shah, Nisha B., McCormick, Robert, DeClercq, Josh, Choi, Leena, Zuckerman, Autumn D.
Format: Artigo
Idioma:Inglês
Publicat: College of Psychiatric & Neurologic Pharmacists 2021
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8120983/
https://ncbi.nlm.nih.gov/pubmed/34026394
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.9740/mhc.2021.05.187
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars